PMDA drug package insert
レミフェンタニル静注用2mg「第一三共」
PMDA Prescription drug · 丸石製薬株式会社 · package insert Aug 25, 2022
Key facts
| Brand names | レミフェンタニル静注用2mg「第一三共」, レミフェンタニル静注用5mg「第一三共」 |
|---|---|
| Nonproprietary names | レミフェンタニル塩酸塩 |
| Companies | 製造販売元／丸石製薬株式会社, 販売元／第一三共株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 全身麻酔用・集中治療用鎮痛剤 |
| Therapeutic category codes | 878219 |
| YJ codes | 8219401D1030, 8219401D2036 |
| Approval numbers | 22800AMX00090, 22800AMX00091 |
| Package insert edition | 第1版 |
| Package insert date | Aug 25, 2022 |
| PMDA document key | 730119_8219401D1030_1 |
| PMDA company code | 730119 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: